Mairs and Power's LLY Position Overview
Mairs and Power (via Mairs & Power INC) currently holds 345,345 shares of Eli Lilly and Company (LLY) worth $371.14 M, representing 3.57% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Mairs and Power has maintained a long-term strategic position in LLY, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2017, adding 468,730 shares. Largest reduction occurred in Q1 2019, reducing 156,371 shares.
Analysis based on 13F filings available since 2013 Q2
Mairs and Power's Eli Lilly and Company (LLY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Eli Lilly and Company (LLY) Trades by Mairs and Power
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -12,832 | Reduce 3.58% | 345,345 | $1074.68 |
| Q3 2025 | -7,150 | Reduce 1.96% | 358,177 | $763.00 |
| Q2 2025 | +534 | Add 0.15% | 365,327 | $779.53 |
| Q1 2025 | +25,526 | Add 7.52% | 364,793 | $825.91 |
| Q4 2024 | -2,694 | Reduce 0.79% | 339,267 | $772.00 |
| Q3 2024 | -8,189 | Reduce 2.34% | 341,961 | $885.94 |
| Q2 2024 | -14,317 | Reduce 3.93% | 350,150 | $905.38 |
| Q1 2024 | -28,222 | Reduce 7.19% | 364,467 | $777.96 |
| Q4 2023 | -33,619 | Reduce 7.89% | 392,689 | $582.92 |
| Q3 2023 | -48,513 | Reduce 10.22% | 426,308 | $537.13 |
| Q2 2023 | -73,617 | Reduce 13.42% | 474,821 | $468.98 |
| Q1 2023 | +65,590 | Add 13.58% | 548,438 | $343.42 |
| Q4 2022 | -15,205 | Reduce 3.05% | 482,848 | $365.84 |
| Q3 2022 | -26,191 | Reduce 5.00% | 498,053 | $323.35 |
| Q2 2022 | -127,268 | Reduce 19.53% | 524,244 | $324.23 |
| Q1 2022 | -11,502 | Reduce 1.73% | 651,512 | $286.37 |
| Q4 2021 | -191 | Reduce 0.03% | 663,014 | $276.22 |
| Q3 2021 | -13,461 | Reduce 1.99% | 663,205 | $231.05 |
| Q2 2021 | -8,068 | Reduce 1.18% | 676,666 | $229.52 |
| Q1 2021 | -28,342 | Reduce 3.97% | 684,734 | $186.82 |
| Q4 2020 | +25,912 | Add 3.77% | 713,076 | $168.84 |
| Q3 2020 | -14,368 | Reduce 2.05% | 687,164 | $148.02 |
| Q2 2020 | -104,547 | Reduce 12.97% | 701,532 | $164.18 |
| Q1 2020 | -48,325 | Reduce 5.66% | 806,079 | $138.72 |
| Q4 2019 | +131,851 | Add 18.25% | 854,404 | $131.43 |
| Q3 2019 | +45,647 | Add 6.74% | 722,553 | $111.83 |
| Q2 2019 | -11,432 | Reduce 1.66% | 676,906 | $110.79 |
| Q1 2019 | -156,371 | Reduce 18.51% | 688,338 | $129.76 |
| Q4 2018 | -93,469 | Reduce 9.96% | 844,709 | $115.72 |
| Q3 2018 | -98,300 | Reduce 9.48% | 938,178 | $107.31 |
| Q2 2018 | -2,815 | Reduce 0.27% | 1.04 M | $85.33 |
| Q1 2018 | +24,812 | Add 2.45% | 1.04 M | $77.37 |
| Q4 2017 | +37,532 | Add 3.84% | 1.01 M | $84.46 |
| Q3 2017 | +105,113 | Add 12.06% | 976,949 | $85.54 |
| Q2 2017 | +152,628 | Add 21.22% | 871,836 | $82.30 |
| Q1 2017 | +468,730 | Add 187.13% | 719,208 | $84.11 |
| Q4 2016 | +8,308 | Add 3.43% | 250,478 | $73.55 |
| Q3 2016 | -4,900 | Reduce 1.98% | 242,170 | $80.26 |
| Q2 2016 | +26,935 | Add 12.24% | 247,070 | $78.75 |
| Q1 2016 | -1,069 | Reduce 0.48% | 220,135 | $72.01 |
| Q4 2015 | -2,377 | Reduce 1.06% | 221,204 | $84.26 |
| Q3 2015 | -44,688 | Reduce 16.66% | 223,581 | $83.69 |
| Q2 2015 | -18,350 | Reduce 6.40% | 268,269 | $83.49 |
| Q1 2015 | -838 | Reduce 0.29% | 286,619 | $72.65 |
| Q4 2014 | -2,370 | Reduce 0.82% | 287,457 | $68.99 |
| Q3 2014 | -1,473 | Reduce 0.51% | 289,827 | $64.85 |
| Q2 2014 | -1,704 | Reduce 0.58% | 291,300 | $62.17 |
| Q1 2014 | -10,233 | Reduce 3.37% | 293,004 | $58.86 |
| Q4 2013 | +6,578 | Add 2.22% | 303,237 | $51.00 |
| Q3 2013 | +14,161 | Add 5.01% | 296,659 | $50.33 |
| Q2 2013 | +282,498 | Add 0.00% | 282,498 | $49.12 |
Mairs and Power's Eli Lilly and Company Investment FAQs
Mairs and Power first purchased Eli Lilly and Company (LLY) in Q2 2013, acquiring 282,498 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power has held Eli Lilly and Company (LLY) for 51 quarters since Q2 2013.
Mairs and Power's largest addition to Eli Lilly and Company (LLY) was in Q1 2017, adding 719,208 shares worth $60.49 M.
According to the latest 13F filing for Q4 2025, Mairs and Power's firm, Mairs & Power INC, owns 345,345 shares of Eli Lilly and Company (LLY), valued at approximately $371.14 M.
As of the Q4 2025 filing, Eli Lilly and Company (LLY) represents approximately 3.57% of Mairs and Power's publicly disclosed stock portfolio, making it one of their key holdings.
Mairs and Power's peak holding in Eli Lilly and Company (LLY) was 1,039,293 shares, as reported at the end of Q1 2018.